Last reviewed · How we verify
PBS and TIV 15%
At a glance
| Generic name | PBS and TIV 15% |
|---|---|
| Sponsor | BiondVax Pharmaceuticals ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above (PHASE1)
- Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults (PHASE1, PHASE2)
- Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly (PHASE2)
- 2013/2017 H7N9 Prime-Boost Interval (PHASE2)
- 2017 A/H7N9 IIV Revaccination (PHASE2)
- Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza (PHASE2)
- Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine (PHASE1)
- Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PBS and TIV 15% CI brief — competitive landscape report
- PBS and TIV 15% updates RSS · CI watch RSS
- BiondVax Pharmaceuticals ltd. portfolio CI